$20.01 Million in Sales Expected for Mersana Therapeutics, Inc. (NASDAQ:MRSN) This Quarter

Equities analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Rating) to announce sales of $20.01 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Mersana Therapeutics’ earnings. The highest sales estimate is $40.00 million and the lowest is $10,000.00. Mersana Therapeutics reported sales of $10,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 200,000%. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Mersana Therapeutics will report full year sales of $26.68 million for the current fiscal year, with estimates ranging from $50,000.00 to $40.00 million. For the next financial year, analysts forecast that the business will post sales of $7.33 million, with estimates ranging from $50,000.00 to $14.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Mersana Therapeutics.

Mersana Therapeutics (NASDAQ:MRSNGet Rating) last posted its quarterly earnings data on Monday, February 28th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.01). Mersana Therapeutics had a negative net margin of 386,500.03% and a negative return on equity of 101.42%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. During the same quarter last year, the company earned ($0.42) EPS.

MRSN has been the topic of several recent research reports. SVB Leerink lowered their price objective on Mersana Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, February 18th. Zacks Investment Research lowered Mersana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 20th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $20.85.

Shares of NASDAQ:MRSN opened at $3.48 on Monday. Mersana Therapeutics has a twelve month low of $3.34 and a twelve month high of $16.65. The company’s 50 day moving average is $4.15 and its 200 day moving average is $5.73. The company has a current ratio of 3.97, a quick ratio of 3.97 and a debt-to-equity ratio of 0.20. The company has a market cap of $290.20 million, a PE ratio of -1.45 and a beta of 2.45.

In other Mersana Therapeutics news, Director Andrew A. F. Hack acquired 1,136,363 shares of the business’s stock in a transaction that occurred on Monday, February 7th. The stock was purchased at an average cost of $4.42 per share, with a total value of $5,022,724.46. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrew A. F. Hack bought 598,086 shares of the stock in a transaction that occurred on Tuesday, April 12th. The shares were purchased at an average price of $4.18 per share, with a total value of $2,499,999.48. Following the completion of the acquisition, the director now directly owns 7,120,116 shares in the company, valued at $29,762,084.88. The disclosure for this purchase can be found here. 5.30% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Sarissa Capital Management LP boosted its stake in shares of Mersana Therapeutics by 7.3% in the 3rd quarter. Sarissa Capital Management LP now owns 4,299,297 shares of the company’s stock valued at $40,542,000 after buying an additional 293,697 shares during the period. Bellevue Group AG boosted its stake in shares of Mersana Therapeutics by 44.9% in the 3rd quarter. Bellevue Group AG now owns 4,261,000 shares of the company’s stock valued at $40,181,000 after buying an additional 1,320,000 shares during the period. State Street Corp boosted its stake in shares of Mersana Therapeutics by 3.2% in the 4th quarter. State Street Corp now owns 4,220,557 shares of the company’s stock valued at $26,252,000 after buying an additional 130,361 shares during the period. Rock Springs Capital Management LP boosted its stake in shares of Mersana Therapeutics by 6.2% in the 3rd quarter. Rock Springs Capital Management LP now owns 3,020,702 shares of the company’s stock valued at $28,485,000 after buying an additional 175,084 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its stake in shares of Mersana Therapeutics by 2.5% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 2,022,895 shares of the company’s stock valued at $19,075,000 after buying an additional 50,000 shares during the period.

Mersana Therapeutics Company Profile (Get Rating)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Featured Stories

Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.